Literature DB >> 20338488

High-density lipoprotein and coronary heart disease: current and future therapies.

Pradeep Natarajan1, Kausik K Ray, Christopher P Cannon.   

Abstract

Coronary heart disease remains a major cause of worldwide morbidity and mortality despite therapeutic advances that control many risk factors such as low-density lipoprotein cholesterol to levels lower than previously possible. Population studies have consistently demonstrated an inverse association between high-density lipoprotein cholesterol (HDL-C) levels with the risk of coronary heart disease. As a result, HDL-C is gaining increasing interest as a therapeutic target. In this review, we explore the protective mechanisms of HDL and how current and future therapies harness these beneficial properties. We offer a biological framework to understand treatment strategies as well as their resultant successes and failures to guide management and future directions. At present, raising HDL-C level holds great promise, on the basis of epidemiology and initial trials, but we await the outcomes of the many large clinical outcomes trials currently under way to define the clinical role of older and novel therapies to raise HDL-C level.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20338488     DOI: 10.1016/j.jacc.2010.01.008

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  63 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Impact of a lifestyle modification program on the metabolic syndrome and associated risk factors in long-term survivors of stem cell transplantation.

Authors:  E Viner Smith; A C Tierney; D Klarica; P Walker; S Avery
Journal:  Bone Marrow Transplant       Date:  2015-12-21       Impact factor: 5.483

Review 3.  Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics.

Authors:  Christopher C Imes; Melissa A Austin
Journal:  Biol Res Nurs       Date:  2012-04-23       Impact factor: 2.522

4.  Psychometric Evaluation of the German Version of the Dietary Fat and Free Sugar-Short Questionnaire.

Authors:  Sophie Pauline Fromm; Annette Horstmann
Journal:  Obes Facts       Date:  2019-09-25       Impact factor: 3.942

5.  Orthotopic liver transplantation in an adult with cholesterol ester storage disease.

Authors:  Graeme K Ambler; Matthew Hoare; Rebecca Brais; Ashley Shaw; Andrew Butler; Paul Flynn; Patrick Deegan; William J H Griffiths
Journal:  JIMD Rep       Date:  2012-07-24

Review 6.  Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?

Authors:  Willibald Hochholzer; Robert P Giugliano
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

Review 7.  Recombinant high-density lipoprotein formulations.

Authors:  Esad Vucic; Robert S Rosenson
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

8.  Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells.

Authors:  Pascale M Ohnsorg; Lucia Rohrer; Damir Perisa; Andreas Kateifides; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis; Arnold von Eckardstein
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

Review 9.  Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis.

Authors:  Jonathan D Smith
Journal:  Curr Opin Investig Drugs       Date:  2010-09

10.  High density lipoproteins-based therapies for cardiovascular disease.

Authors:  Xuan Gao; Shujun Yuan
Journal:  J Cardiovasc Dis Res       Date:  2010-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.